References
- 1. FAUBION WA, LOFTUS EV, HARMSEN WS, ZINSMEISTER AR, SANDBORN WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121(2):255-60.
- 2. TURNER D, WALSH CM, STEINHART AH, GRIFFITHS AM. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5(1):103-10.
- 3. HINDRYCKX P, JAIRATH V, D'HAENS G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016; 13(11):654-64.
- 4. RUTGEERTS P, SANDBORN WJ, FEAGAN BG, REINISCH W, OLSON A, JOHANNS J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76.
- 5. D'HAENS G, LEMMENS L, GEBOES K, VANDEPUTTE L, VAN ACKER F, MORTELMANS L et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001; 120(6):1323-9.
- 6. NARULA N, MARSHALL JK, COLOMBEL JF, LEONTIADIS GI, WILLIAMS JG, MUQTADIR Z et al. Systematic review and meta-analysis: Infliximab or Cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol. 2016; 111(4):477-91.
- 7. OGATA H, MATSUI T, NAKAMURA M, IIDA M, TAKAZOE M, SUZUKI Y et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55(9):1255-62.
- 8. OGATA H, KATO J, HIRAI F, HIDA N, MATSUI T, MATSUMOTO T et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012; 18(5):803-8.
- 9. YAMAMOTO T, SHIMOYAMA T, UMEGAE S, MATSUMOTO K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Aliment Pharmacol Ther. 2016; 43(6):705-16.
- 10. ENDO K, ONODERA M, SHIGA H, KUROHA M, KIMURA T, HIRAMOTO K et al. A comparison of short- and long-term therapeutic outcomes of Infliximab - versus Tacrolimus-based strategies for steroid-refractory ulcerative colitis. Gastroenterol Res Pract. 2016:11. 3162595.
- 11. NUKI Y, ESAKI M, ASANO K, MAEHATA Y, UMENO J, MORIYAMA T et al. Comparison of the therapeutic efficacy and safety between Tacrolimus and Infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand J Gastroenterol. 2016; 51(6):700-5.
- 12. LENNARD-JONES JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170:2-6; discussion 16-9.
- 13. LEWIS JD, CHUAI S, NESSEL L, LICHTENSTEIN GR, ABERRA FN, ELLENBERG JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14(12):1660-6. doi:10.1002/ibd.20520.
- 14. SANDBORN WJ, COLOMBEL JF, D'HAENS G, VAN ASSCHE G, WOLF D, KRON M et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013; 37(2):204-13.
- 15. LAHARIE D, BOURREILLE A, BRANCHE J, ALLEZ M, BOUHNIK Y, FILIPPI J et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012; 380(9857):1909-15.
- 16. WILLIAMS JG, ALAM MF, ALRUBAIY L, ARNOTT I, CLEMENT C, COHEN D et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed method, open-label, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2016; 1(1):15-24.
- 17. VOIOSU T, BENGUŞ A, BĂLĂNESCU P, DINU R, VOIOSU A, BĂICUŞ C et al. Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and Serum tumor necrosis factor α in patients with ulcerative colitis. Rom J Intern Med. 2015; 53(3):253-60.
- 18. DOTAN I, RON Y, YANAI H, BECKER S, FISHMAN S, YAHAV L et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014; 20(12):2247-59.
- 19. BRANDSE JF, MATHÔT RA, VAN DER KLEIJ D, RISPENS T, ASHRUF Y, JANSEN JM et al. Pharmacokinetic features and presence of antidrug antibodies associate with response to Infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2016;14(2):251-8.e1-2.